1. Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing
- Author
-
McAuley, Grace E, Yiu, Gloria, Chang, Patrick C, Newby, Gregory A, Campo-Fernandez, Beatriz, Fitz-Gibbon, Sorel T, Wu, Xiaomeng, Kang, Sung-Hae L, Garibay, Amber, Butler, Jeffrey, Christian, Valentina, Wong, Ryan L, Everette, Kelcee A, Azzun, Anthony, Gelfer, Hila, Seet, Christopher S, Narendran, Aru, Murguia-Favela, Luis, Romero, Zulema, Wright, Nicola, Liu, David R, Crooks, Gay M, and Kohn, Donald B
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Research ,Rare Diseases ,Genetics ,Stem Cell Research ,Biotechnology ,Stem Cell Research - Nonembryonic - Human ,Regenerative Medicine ,Transplantation ,Development of treatments and therapeutic interventions ,5.2 Cellular and gene therapies ,Humans ,Animals ,Mice ,T-Lymphocytes ,Severe Combined Immunodeficiency ,Gene Editing ,Mice ,SCID ,CD3 Complex ,Receptors ,Antigen ,T-Cell ,CD3D severe combined immune deficiency ,CITE-seq ,artificial thymic organoid ,base editing ,hematopoietic stem and progenitor cells ,Biological Sciences ,Medical and Health Sciences ,Developmental Biology ,Biological sciences ,Biomedical and clinical sciences - Abstract
CD3δ SCID is a devastating inborn error of immunity caused by mutations in CD3D, encoding the invariant CD3δ chain of the CD3/TCR complex necessary for normal thymopoiesis. We demonstrate an adenine base editing (ABE) strategy to restore CD3δ in autologous hematopoietic stem and progenitor cells (HSPCs). Delivery of mRNA encoding a laboratory-evolved ABE and guide RNA into a CD3δ SCID patient's HSPCs resulted in a 71.2% ± 7.85% (n = 3) correction of the pathogenic mutation. Edited HSPCs differentiated in artificial thymic organoids produced mature T cells exhibiting diverse TCR repertoires and TCR-dependent functions. Edited human HSPCs transplanted into immunodeficient mice showed 88% reversion of the CD3D defect in human CD34+ cells isolated from mouse bone marrow after 16 weeks, indicating correction of long-term repopulating HSCs. These findings demonstrate the preclinical efficacy of ABE in HSPCs for the treatment of CD3δ SCID, providing a foundation for the development of a one-time treatment for CD3δ SCID patients.
- Published
- 2023